Dr. Reddy's Q3 FY26 Revenue at ₹8,727 Cr, Up 4.4% YoY
Dr. Reddy's reported Q3 FY26 consolidated revenue of ₹8,727 crore, a 4.4% YoY increase. EBITDA was ₹2,049 crore (up 11% YoY), and PAT was ₹1,210 crore (up 14% YoY). The company highlighted strategic collaborations, new product launches like Hevaxin®, and a commitment to Net Zero Climate Targets by FY2045.
The results show steady growth and strategic advancements, which are positive for the company's outlook. However, the growth rates are moderate, and there were some product-specific headwinds mentioned, suggesting a medium impact rather than high.
The company reported positive year-on-year growth in revenue, EBITDA, and PAT, along with strategic business developments and a commitment to sustainability targets.
Dr. Reddy's Laboratories Limited announced its unaudited financial results for the third quarter ended December 31, 2025. The company reported consolidated revenues of ₹8,727 crore, marking a 4.4% increase year-on-year and a 0.9% increase quarter-on-quarter.
EBITDA for the quarter stood at ₹2,049 crore, a 11% increase year-on-year and a 13% increase quarter-on-quarter, with an EBITDA margin of 23.5%. Profit Before Tax (PBT) was ₹1,543 crore, up 18% year-on-year and 16% quarter-on-quarter, representing 17.7% of revenues. Profit After Tax (PAT) attributable to equity shareholders was ₹1,210 crore, a 14% increase year-on-year and a 16% increase quarter-on-quarter, with a PAT margin of 13.9%.
The company highlighted double-digit growth in its base business and steady overall profitability despite product-specific headwinds. Key business highlights include a strategic collaboration with Immutep for the commercialization of an oncology drug in emerging markets, the launch of Hevaxin® in India, and receiving Marketing Authorisation for Semaglutide injection. The company also filed a BLA for an abatacept biosimilar and received approvals for a denosumab biosimilar.
Dr. Reddy's reported a net cash surplus of ₹3,069 crore as of December 31, 2025. The company also announced Science-Based Net Zero Climate Targets, committing to achieve this by FY2045, making it the only Indian pharma company to do so.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.